Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.

Abstract

Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.

• Authors: Jane N Winter
• Journal: Clinical lymphoma (Clin Lymphoma) Vol. 5 Suppl 1 Pg. S22-6 (Oct 2004) ISSN: 1526-9655 [Print] United States
• PMID: 15498146 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antigens, CD20
• Yttrium Radioisotopes
• ibritumomab tiuxetan

Topics

• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antigens, CD20
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Clinical Trials as Topic
• Combined Modality Therapy
• Humans
• Lymphoma, Non-Hodgkin (drug therapy, immunology, radiotherapy)
• Radioimmunotherapy (methods)
• Stem Cell Transplantation
• Transplantation, Autologous
• Yttrium Radioisotopes (administration & dosage, therapeutic use)